Results 211 to 220 of about 1,454,174 (267)

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Managing aggressive vertebral hemangiomas with combination therapy: a case report and literature review. [PDF]

Front Oncol
Jia Z, Zheng J, Zhong X, Xiu X, Xie A, Liu G, Chen Y.   +6 more
europepmc   +1 more source

Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab [PDF]

Liana Victory, Gregg Murray, Claire Quigley, Stephanie Bowe, Clióna Feighery, Anne Fortune, Ian A. McDonald   +6 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis. [PDF]

Front Immunol
Wang B, Chu Y, Zhang C, Guo S.
europepmc   +1 more source

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini, Elizabeth Calton, Qiong Gao, Harvey Che, Evon Poon, Yann Jamin, Barbara Martins Da Costa, Karen Barker, Sumana Shrestha, J. Ciaran Hutchinson, Simran Dhariwal, Angharad Goodman, Elaine Del Nery, Pierre Gestraud, Jaydutt Bhalshankar, Yasmine Iddir, Elnaz Saberi-Ansari, Alexandra Saint‐Charles, Birgit Geoerger, Maria Eugénia Marques Da Costa, Cécile Pierre‐Eugène, Isabelle Janoueix‐Lerosey, Didier Decaudin, Fariba Némati, Ángel M. Carcaboso, Didier Surdez, Olivier Delattre, Sally L. George, Louis Chesler, Deborah A. Tweddle, Gudrun Schleiermacher   +34 more
openalex   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Less combination therapy and more fistulotomy in perianal fistulizing Crohn's disease in the elderly. [PDF]

Int J Colorectal Dis
Arjafallah Goulet O, Brochard C, Siproudhis L, Etienney I.   +3 more
europepmc   +1 more source

SURGICAL TREATMENT OF EXTENDED PHLEGMONUS IN COMBINATION WITH SYSTEMIC OZONE THERAPY

Popa, Veaceslav, Bour, Alin, Bodrug, Nicolae   +2 more
openalex   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source